Myriad takes cancer diagnostic to U.K. and Ireland

MYGN entered the predictive medicine market in the U.K. and Ireland by striking an exclusive marketing agreement with Rosgen (Roslin, U.K.) to introduce MYGN's BRACAnalysis breast and ovarian cancer d...